These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 29327946)

  • 1. Posttranscriptional Regulation of Human Antigen R by miR-133b Enhances Docetaxel Cytotoxicity Through the Inhibition of ATP-Binding Cassette Subfamily G Member 2 in Prostate Cancer Cells.
    Liu H; Song X; Hou J; Zhao Z; Chang J
    DNA Cell Biol; 2018 Mar; 37(3):210-219. PubMed ID: 29327946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploiting a novel miR-519c-HuR-ABCG2 regulatory pathway to overcome chemoresistance in colorectal cancer.
    To KK; Leung WW; Ng SS
    Exp Cell Res; 2015 Nov; 338(2):222-31. PubMed ID: 26386386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2).
    Jiao X; Zhao L; Ma M; Bai X; He M; Yan Y; Wang Y; Chen Q; Zhao X; Zhou M; Cui Z; Zheng Z; Wang E; Wei M
    Breast Cancer Res Treat; 2013 Jun; 139(3):717-30. PubMed ID: 23780685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Silencing of ABCG2 by MicroRNA-3163 Inhibits Multidrug Resistance in Retinoblastoma Cancer Stem Cells.
    Jia M; Wei Z; Liu P; Zhao X
    J Korean Med Sci; 2016 Jun; 31(6):836-42. PubMed ID: 27247490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MiR-487a resensitizes mitoxantrone (MX)-resistant breast cancer cells (MCF-7/MX) to MX by targeting breast cancer resistance protein (BCRP/ABCG2).
    Ma MT; He M; Wang Y; Jiao XY; Zhao L; Bai XF; Yu ZJ; Wu HZ; Sun ML; Song ZG; Wei MJ
    Cancer Lett; 2013 Oct; 339(1):107-15. PubMed ID: 23879965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ABCG2 is required for self-renewal and chemoresistance of CD133-positive human colorectal cancer cells.
    Ma L; Liu T; Jin Y; Wei J; Yang Y; Zhang H
    Tumour Biol; 2016 Sep; 37(9):12889-12896. PubMed ID: 27449042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual responsive micelles capable of modulating miRNA-34a to combat taxane resistance in prostate cancer.
    Lin F; Wen D; Wang X; Mahato RI
    Biomaterials; 2019 Feb; 192():95-108. PubMed ID: 30447399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of miR-133b and RB1CC1 as independent predictors for biochemical recurrence and potential therapeutic targets for prostate cancer.
    Li X; Wan X; Chen H; Yang S; Liu Y; Mo W; Meng D; Du W; Huang Y; Wu H; Wang J; Li T; Li Y
    Clin Cancer Res; 2014 May; 20(9):2312-25. PubMed ID: 24610824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Docetaxel-triggered SIDT2/NOX4/JNK/HuR signaling axis is associated with TNF-α-mediated apoptosis of cancer cells.
    Wang LJ; Chiou JT; Lee YC; Chang LS
    Biochem Pharmacol; 2022 Jan; 195():114865. PubMed ID: 34863979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overcoming chemoresistance in prostate cancer with Chinese medicine Tripterygium wilfordii via multiple mechanisms.
    Wang Z; Ravula R; Shi L; Song Y; Yeung S; Liu M; Lau B; Hao J; Wang J; Lam CW; Chow MS; Huang Y
    Oncotarget; 2016 Sep; 7(38):61246-61261. PubMed ID: 27487134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-27b and miR-34a enhance docetaxel sensitivity of prostate cancer cells through inhibiting epithelial-to-mesenchymal transition by targeting ZEB1.
    Zhang G; Tian X; Li Y; Wang Z; Li X; Zhu C
    Biomed Pharmacother; 2018 Jan; 97():736-744. PubMed ID: 29102917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Upregulated miR-132 in Lgr5
    Zhang L; Guo X; Zhang D; Fan Y; Qin L; Dong S; Zhang L
    Mol Carcinog; 2017 Sep; 56(9):2022-2034. PubMed ID: 28383763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
    Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
    Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Establishment and characterization of multi-drug resistant, prostate carcinoma-initiating stem-like cells from human prostate cancer cell lines 22RV1.
    Liu T; Xu F; Du X; Lai D; Liu T; Zhao Y; Huang Q; Jiang L; Huang W; Cheng W; Liu Z
    Mol Cell Biochem; 2010 Jul; 340(1-2):265-73. PubMed ID: 20224986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
    Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
    Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TUBB3 Reverses Resistance to Docetaxel and Cabazitaxel in Prostate Cancer.
    Sekino Y; Han X; Kawaguchi T; Babasaki T; Goto K; Inoue S; Hayashi T; Teishima J; Shiota M; Yasui W; Matsubara A
    Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31412591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1.
    Wang Y; Lieberman R; Pan J; Zhang Q; Du M; Zhang P; Nevalainen M; Kohli M; Shenoy NK; Meng H; You M; Wang L
    Mol Cancer; 2016 Nov; 15(1):70. PubMed ID: 27832783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of Krüppel-Like Factor 4 in the Maintenance of Chemoresistance of Anaplastic Thyroid Cancer.
    Lee SI; Kim DK; Seo EJ; Choi EJ; Kwon YW; Jang IH; Lee JC; Kim HY; Shong M; Kim JH; Kim SJ
    Thyroid; 2017 Nov; 27(11):1424-1432. PubMed ID: 28920531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro and in vivo prostate cancer metastasis and chemoresistance can be modulated by expression of either CD44 or CD147.
    Hao J; Madigan MC; Khatri A; Power CA; Hung TT; Beretov J; Chang L; Xiao W; Cozzi PJ; Graham PH; Kearsley JH; Li Y
    PLoS One; 2012; 7(8):e40716. PubMed ID: 22870202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversal of multidrug resistance by Marsdenia tenacissima and its main active ingredients polyoxypregnanes.
    To KKW; Wu X; Yin C; Chai S; Yao S; Kadioglu O; Efferth T; Ye Y; Lin G
    J Ethnopharmacol; 2017 May; 203():110-119. PubMed ID: 28363522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.